Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19

• DOI: 10.3349/ymj.2022.63.5.430
• Publication Date: 2022-04-27T07:44:47Z
• Authors: Jin Yeong Hong; Jae-Hoon Ko; Jinyoung Yang; Soyoung Ha; Eliel Nham; Kyungmin Huh; Sun Young Cho; Cheol-In Kang; Doo Ryeon Chung; Jin Yang Baek; You Min Sohn; Hyo Jung Park; Beomki Lee; Hee Jae Huh; Eun-Suk Kang; Gee Young Suh; Chi Ryang Chung; Kyong Ran Peck
• Keywords: Tocilizumab; Clinical endpoint; Convalescence

Real-world experience with tocilizumab in combination dexamethasone patients severe coronavirus disease (COVID-19) needs to be investigated.A retrospective cohort study was conducted evaluate the effect of severity-adjusted dosing for COVID-19 from August 2020 2021. The primary endpoint 30-day clinical recovery, which defined as no oxygen requirement or referral after recovery.A total 66 were evaluated, including 33 (Dexa) group and plus (DexaToci) group. DexaToci showed a statistically significant benefit compared Dexa (p=0.024). In multivariable analyses, peak FiO2 within 3 days consistently recovery (all p<0.05). significantly steeper decrease (-4.2±2.6) than (-2.7±2.6; p=0.021) by hospital day 15. duration shorter (median, 10.0 vs. 17.0 days; p=0.006). Infectious complications cellular humoral immune responses against acute respiratory syndrome 2 (SARS-CoV-2) convalescence stage not different between two groups.A treatment improved without increasing infectious hindering response SARS-CoV-2.